Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-03-05 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于对外投资成立参股子公司暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by a publicly listed company regarding its external investment to establish a joint venture subsidiary and related party transactions. It details the investment structure, parties involved, governance, financial data of partners, and approvals from the board, independent directors, and supervisory board. The document is an announcement of a corporate action related to investment and related party transactions, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather discloses a corporate governance and investment event. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2021-03-05 Chinese
第四届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company regarding approval of an external investment and related party transaction. It includes details about the meeting, attendance, and voting results. It references a separate announcement published on the official disclosure website for more details. The document is short (745 characters) and serves as an official meeting resolution announcement rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-03-05 Chinese
上海荣正投资咨询股份有限公司关于公司2021年限制性股票激励计划授予事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to the 2021 restricted stock incentive plan grant for the company 健帆生物科技集团股份有限公司. It includes detailed explanations of the stock incentive plan, conditions for granting restricted stock, approval and authorization processes, and the impact on financial status and operating results. The document is not a general annual or quarterly financial report, nor is it a simple announcement or certification. It is a specialized advisory report on a capital incentive plan, which aligns with the category of Capital/Financing Update (CAP) as it relates to company financing activities and equity incentives. The document length (6730 characters) and content confirm it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2021-02-26 Chinese
独立董事关于第四届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on adjustments and grant of restricted stock incentive plan matters for the year 2021. It references compliance with regulatory guidelines and company rules, and provides an independent opinion on the stock incentive plan approval and grant. The document is not a full financial report, earnings release, or management discussion, but rather a formal opinion related to governance and board decisions on stock incentives. It does not announce voting results or a meeting, nor is it a proxy solicitation or remuneration report. The content fits best under Board/Management Information (MANG) as it relates to board-level decisions and opinions on management incentive plans.
2021-02-26 Chinese
关于调整2021年限制性股票激励计划相关事项的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding adjustments to the company's 2021 restricted stock incentive plan, including details about the decision-making process, approvals, and legal and financial advisor opinions. It does not contain financial statements or detailed financial performance data. The document is relatively short (3125 characters) and focuses on corporate governance and incentive plan adjustments rather than financial results or reports. This type of announcement fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about corporate actions related to stock incentives, not a full report or financial statement.
2021-02-26 Chinese
关于向公司2021年限制性股票激励计划激励对象授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the granting of restricted stock under the company's 2021 restricted stock incentive plan. It includes specifics such as grant dates, prices, quantities, eligibility criteria, performance conditions, approvals by the board and shareholders, legal opinions, and financial advisor opinions. The content focuses on the stock incentive plan implementation and related disclosures rather than financial results, earnings, or management changes. This type of document is typically classified as a Capital/Financing Update (CAP) because it relates to equity-based compensation and issuance of shares to employees and management as part of a stock incentive plan.
2021-02-26 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.